'The Top Line' podcast: Biogen's overhaul reaches CEO level, the most influential people in biopharma, plus this week's headlines

Biogen has been battling for a while now over Aduhelm's controversial FDA approval and subsequent narrow Medicare coverage decision. And those struggles have resulted in significant company reorganization, including the departure of CEO Michel Vounatsos. After a five-year term, he is stepping down, and a hunt for his replacement is already underway. Also under discussion is the Fierce newsroom's assessment of the most influential people in biopharma—from CEOs to entrepreneurs, scientists and regulatory experts. And the Fierce Madness drug naming championship is the buzz around the newsroom this week, with names that sound like they're spells straight out of a Harry Potter book.

To learn more about the topics in this episode:

The Top Line is produced by senior multimedia producer Teresa Carey, with editor-in-chief Tracy Staton, managing editor Querida Anderson, senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.

Follow The Top Line on iTunesSpotifyAmazoniHeart Radio or wherever you get your podcasts.

To Listen to More Episodes from The Top Line